Press release
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs CELEBRATION, Fla., Oct.
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will present data related to clinical study outcomes and its early access programs via both oral and poster presentations at the upcoming 52nd Child Neurology Society (CNS) Annual Meeting. This meeting will be held October 4-7, 2023, in Vancouver, Canada. The presentations will focus on arimoclomol, Zevra’s late-stage pipeline program in development for the treatment of Niemann-Pick Disease type C (NPC), including 48 months of efficacy and safety data captured through the double-blind and open-label extension phases of the registrational trial, as well as methodology related to establishing an early access program with real-world data collection capabilities. “Our team is eager to highlight our arimoclomol program at the 52nd CNS Annual Meeting and engage with the key child neurologists who are treating devastating conditions like NPC where few therapeutic options exist,” said Daniel Gallo, PhD, Senior Vice President of Medical Affairs and Advocacy for Zevra. “The arimoclomol data demonstrate the importance of understanding the long-term efficacy and treatment approach for this potential new therapy for NPC.” Oral Presentation Details: Title:Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002Presenter:Marc Patterson, MD, Professor of Neurology, Pediatrics, and Medical Genetics, Mayo Clinic College of Medicine and Science, Rochester, MNSession:Platform 3Time:Friday, October 6th at 2:15 - 4:00 p.m.Location:Ballroom BC Poster Presentation Details: Title:Real World Data Collection in Niemann-Pick Disease Type C – Data from Expanded Access Program with ArimoclomolPresenter:Elizabeth Berry Kravis, MD, PhD, Professor of Pediatrics, Neurological Sciences, and Biochemistry, Rush Medical College, Rush University Medical Center, Chicago, ILPoster:#100Poster Review:Thursday, Oct 5, 2023, at 12:30 - 2:00 p.m. and 5:30 - 7:30 p.m. The Zevra team will also be on site throughout the event and invites attendees to connect at Booth #518 to learn more about how Zevra is supporting the child neurolo...